Facebook Tracking Image

National Comprehensive Cancer Network

Educational Events & Programs

Oncology Policy Summit Banner

Virtual Summit > Registration Opening Soon!

September 9, 2020 
Live Webinar
10:00 AM – 2:05 PM EDT



The Summit will explore diverse perspectives related to emerging models to drive down healthcare costs in the United States and their potential impact on access to high-quality cancer care. Major themes of the summit will include an overview of legislative and regulatory efforts to reduce health costs, the current state of value-based payment models, and the impact of these models on providers and patients with cancer. The summit will also explore the unique implications of policies intended to curb costs for rural and other underserved populations.

Please check back often for additional agenda updates regarding this summit. If you have any questions, please contact Terrell Johnson, Manager, Policy and Advocacy, johnson@nccn.org.


10:00 – 10:05 AM

Welcome and Introductions
Alyssa Schatz, MSW, National Comprehensive Cancer Network

10:10 – 10:55 AM

Innovative Reimbursement Models in Medicare and Medicaid

11:00 – 11:45 AM

Fireside Chat: Legislative Proposals to Reduce Cost and Considerations for Protecting Access to High Quality Cancer Care
Moderated by Clifford Goodman, PhD, The Lewin Group

11:45 – 11:55 AM


12:00 – 1:15 PM

Panel Discussion – Perspectives on the Future of Lowering Costs in the American Healthcare System and Implication’s for the Oncology Community
Moderated by Clifford Goodman, PhD, The Lewin Group

Ruth O’Regan, MD
University of Wisconsin Carbone Cancer Center

Gena Cook
Navigating Cancer

1:20 – 1:55 PM

Getting Providers and Payers to the Other Side: Best Practices for Succeeding in Commercial Value-Based Agreement’s

David Rubin
Memorial Sloan Kettering Cancer Center

2:00 – 2:05 PM

Wrap-up and Conclusions
Terrell Johnson, MPA, National Comprehensive Cancer Network

*Topics subject to change.


Supported by Adaptive; ADC Therapeutics; AmerisourceBergen; Apobiologix; Astellas; AstraZeneca through its NCCN Corporate Council Membership; BeiGene, Ltd.; bluebird bio; Boehringer Ingelheim Pharmaceuticals, Inc.; Dendreon Pharmaceuticals; Eisai Inc; EMD Serono; Exelixis; Foundation Medicine, Inc.; Genentech; GSK; Heron; Incyte Corporation; Janssen Oncology; Pharmaceutical Companies of Johnson & Johnson; Kite, a Gilead Company; Lilly; MorphoSys US, Inc.; Novartis; Regeneron Pharmaceuticals, Inc.; Sun Pharma Oncology; Takeda; and Verastem Oncology. Supported by an independent educational grant from Merck & Co., Inc. This activity was made possible by Pharmacyclics, an AbbVie Company.

As of July 1, 2020.

Access the Library of White Papers!

NCCN offers a broad library of white papers from previous summits that may be pertinent to your organization.

View Supporter Opportunities.

NCCN offers organizations various supporter opportunities.